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Next-generation sequencing approaches have enabled 
the sequencing of the human cancer genome at un-
precedented speed, resolution and cost. Several such 
studies have recently been reported in both oestrogen 
receptor-positive and oestrogen receptor-negative breast 
cancer [1-3]. Results of these cancer-genome sequencing 
studies have highlighted the tremendous complexity and 
heterogeneity between cancer genomes from diﬀ  erent 
patients with the same breast cancer histopathological 
phenotype (inter-tumoural heterogeneity). For example, 
none of the novel fusion genes identiﬁ  ed by Stephens and 
colleagues were present more than once in any of the 24 
cancers studied, and three expressed in-frame fusion 
genes selected for follow-up were not present in an 
additional 288 breast cancers studied [2]. In a further 
twist to breast cancer complexity, Navin and colleagues 
have recently described profound heterogeneity within 
individual breast tumours (intra-tumoural hetero-
geneity), where multiple tumour subpopulations have 
been identiﬁ  ed, each with distinct genomic proﬁ  les [4].
Both patterns of heterogeneity present challenges from 
a therapeutic perspective. Heterogeneity within an 
individual tumour raises the likelihood that if driver 
mutations can be identiﬁ  ed and subsequently targeted, 
resistance to therapy may develop rapidly due to the 
genomic variation from one cancer cell clone to the next, 
as has recently been reported in non-small cell lung 
cancer [5]. Inter-tumoural heterogeneity implies that 
potentially diﬀ  erent driver mutations may be responsible 
for cancer cell survival and growth from one patient to 
the next.
Given the cost (approaching $1 billion [6]) and lead 
time (10 to 15 years) in drug development, it is economi-
cally challenging to develop the next generation of 
anticancer drugs against each target, suitable for only a 
small cohort of patients in an individualised approach. 
Furthermore, the prohibitive costs and challenges 
imposed by both industry and regulators for combining 
targeted therapeutics may mitigate against the develop-
ment of rational drug combinations to target intra-
tumoural heterogeneity to limit the acquisition of drug 
resistance.
Such genomic heterogeneity both between and within 
individual tumours presents an economically intractable 
problem requiring a change in drug development strate-
gic approaches. Cancer cell heterogeneity and the con-
tinued genomic diversity acquired from one cancer cell 
division to another may promote cancer cell stress or 
dependence on alternative cellular pathways that are 
potentially targetable, as witnessed by success with 
poly(ADP-ribose) polymerase inhibition in patients who 
harbour germline BRCA1/2 mutations [7,8].
Recent observations clearly indicate that other patterns 
of genome instability leading to tumour heterogeneity, 
initiated by speciﬁ   c defects in the mismatch repair 
apparatus [9] or chromosome mis-segregation, may also 
be targetable. Unequal segregation of whole chromo-
somes at mitosis generates heterogeneity that is 
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© 2011 BioMed Central Ltdassociated with poor prognosis in solid tumours [10] and 
early tumour relapse in animal models [11]. Studies in 
model eukaryotic organisms have identiﬁ  ed that aneu-
ploidy is associated with vulnerability to inhibitors of 
protein folding and synthesis [12]. Finally, evidence is 
emerging that cancer cell heterogeneity can be a rever-
sible epigenetic event contributing to drug tolerance in 
cancer cell models that can be attenuated through insulin-
like growth factor-1 receptor pathway inhibition [13].
Next-generation sequencing studies have revealed new 
patterns of genomic instability. Stephens and colleagues 
identiﬁ   ed tandem duplications occurring in large 
numbers in oestrogen receptor-negative–progesterone 
receptor-negative breast cancers, and speculate that this 
pattern of genomic instability may be attributable to an 
underlying defective DNA maintenance process [2]. 
Deﬁ   ning the under  lying mechanisms responsible for 
these tandem duplica  tions and potential strategies to 
exploit them is clearly important.
Th  e identiﬁ   cation of common targets upon which 
tumours rely to sustain and develop heterogeneity is now 
an experimentally tractable problem in cancer medicine. 
Inactivation of key cancer cell survival speciﬁ  c to these 
processes might enhance the eﬃ   cacy of anticancer drug 
treatment. Since normal cells may not routinely require 
such survival pathways due to their genetic identity from 
cell to cell, the development of anticancer drugs that 
inactivate genome-instability survival pathways might 
have an enhanced therapeutic window. Importantly, such 
an approach may present a more economically viable 
solution compared with the current strategy of targeting 
diverse driver mutations in molecularly heterogeneous 
tumours.
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